Fundraising FoxYumanity Therapeutics
Boston, US · Delaware corporation · 7 known investors
Find your way into Yumanity Therapeutics
Sign up to find every way you can get introduced to Yumanity Therapeutics
- Your email: who you already know at Yumanity Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Yumanity Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Neurodegenerative disease drug discovery correcting misfolded-protein cellular pathologies. IPO as YMTX.
Founders & leadership
NA
N. Anthony ColesFounder
RP
Richard PetersExecutive
PM
Paulash MohsenExecutive
BR
Brigitte RobertsonExecutive
RA
JW
Jeffery W. KellyNamed on SEC filing
CB
Cecil B. PickettNamed on SEC filing
LZ
Lynne ZydowskyNamed on SEC filing
Board
PL
Patricia L. AllenBoard director
DA
David ArkowitzBoard director
KC
Kim C. DrapkinBoard director
Investors · 7
Altium Capitallisted by Altium CapitalNew York
How we know: Altium Capital's portfolio page · Not right? Tell us
Dolby Family Ventureslisted by Dolby Family VenturesSan Francisco
How we know: Dolby Family Ventures's portfolio page · Not right? Tell us
Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M
How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us
Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M
How we know: Sanofi Ventures's portfolio page · Not right? Tell us
AlexandriareportedPasadena
How we know: funding news · Not right? Tell us
Fidelity InvestmentsreportedBoston
How we know: funding news · Not right? Tell us
REDMILEreportedSan Francisco
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$78.1M disclosed across 4 of 5 rounds · 2014–2023
▶$2.9MofferedOct 2023 · 1 investors · BiotechnologyRule 506(b)
▶$2.9MofferedOct 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shawn P. IadonatoExecutive Officer, Director
- Pauline KennyExecutive Officer
- Craig W. PhilipsExecutive Officer
- Richard PetersDirector
- Marion R. FooteDirector
- Thierry GuillaudeuxExecutive Officer
- Raymond BartoszekDirector
- Keith A. BakerExecutive Officer
- Kimberlee C. DrapkinDirector
- Scott J. DyllaDirector
- David ArkowitzDirector
- Offering amount
- $2.9M
- Sales commissions
- $210K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedDec 2022 · 17 investors · BiotechnologyRule 506(b)
▶$7.5MraisedDec 2022 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Raymond BartoszekDirector
- David ArkowitzDirector
- Keith A. BakerExecutive Officer
- Richard PetersDirector
- Marion R. FooteDirector
- Shawn IadonatoExecutive Officer, Director
- Craig W. PhilipsExecutive Officer
- Offering amount
- $30M
- Amount sold
- $7.5M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$33.6MraisedJan 2021 · 16 investors · Other Health CareRule 506(b)
▶$33.6MraisedJan 2021 · 16 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Richard PetersExecutive Officer, Director
- N. Anthony ColesExecutive Officer, Director
- Paulash MohsenExecutive Officer
- Brigitte RobertsonExecutive Officer
- Patricia L. AllenDirector
- David ArkowitzDirector
- Kim C. DrapkinDirector
- Richard A. HeymanDirector
- Jeffery W. KellyDirector
- Cecil B. PickettDirector
- Lynne ZydowskyDirector
- Offering amount
- $33.6M
- Amount sold
- $33.6M
- Sales commissions
- $1.7M
- Placement agents
- Jefferies LLC
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$22MraisedSep 2015 · 9 investors · BiotechnologyRule 506(b)
▶$22MraisedSep 2015 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JEFFERY W. KELLYDirector
- M. JAMES BARRETTDirector
- CONOR WALSHEDirector
- CHRISTOPHER K. MIRABELLIDirector
- IRENA MELNIKOVAPromoter
- CHRISTOPHER T. WALSHDirector
- MEENU CHHABRAExecutive Officer, Director
- NADIA USTARIZExecutive Officer
- JANET SMARTExecutive Officer
- STEPHEN KNIGHTDirector
- HENRY B. SKINNERDirector
- BERNARD DAVITIANDirector
- Offering amount
- $28M
- Amount sold
- $22M
- Sales commissions
- $720K
- Proceeds to insiders
- $720K
- Placement agents
- Irena Melnikova
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedSep 2015 · 8 investors · BiotechnologyRule 506(b)
▶$15MraisedSep 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- MEENU CHHABRAExecutive Officer, Director
- BERNARD DAVITIANDirector
- NADIA USTARIZExecutive Officer
- JANET SMARTExecutive Officer
- STEPHEN KNIGHTDirector
- M. JAMES BARRETTDirector
- CHRISTOPHER MIRABELLIDirector
- CONOR WALSHEDirector
- CHRISTOPHER WALSHDirector
- JEFFERY KELLYDirector
- HENRY SKINNERDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Acquisitions · 1
Early investors' stakes continue via these dealsProteostasis Therapeutics
Developing disease-modifying therapeutics for diseases of protein processing, with a lead program in cystic fibrosis.
Frequently asked questions
- What does Yumanity Therapeutics do?
- Neurodegenerative disease drug discovery correcting misfolded-protein cellular pathologies. IPO as YMTX.
- Who founded Yumanity Therapeutics?
- Yumanity Therapeutics was founded by N. Anthony Coles.
- Who are Yumanity Therapeutics's investors?
- Yumanity Therapeutics's investors include Altium Capital, Dolby Family Ventures, Pfizer Venture Investments, Sanofi Ventures, Alexandria, Fidelity Investments, REDMILE.
- How much funding has Yumanity Therapeutics raised?
- Yumanity Therapeutics has disclosed $78.1M raised across 4 of its 5 known rounds.
- Where is Yumanity Therapeutics headquartered?
- Yumanity Therapeutics is headquartered in Boston, US.